BDTX
Black Diamond Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$168.47M
P/E Ratio
—
EPS
$-0.77
Beta
3.35
52W High
$4.94
52W Low
$1.88
50-Day MA
$2.51
200-Day MA
$2.94
Dividend Yield
—
Profit Margin
32.00%
Forward P/E
8.33
PEG Ratio
—
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $70.00M |
| Gross Profit (TTM) | $70.00M |
| EBITDA | $20.20M |
| Operating Margin | 28.40% |
| Return on Equity | 22.90% |
| Return on Assets | 9.35% |
| Revenue/Share (TTM) | $1.23 |
| Book Value | $1.96 |
| Price-to-Book | 1.65 |
| Price-to-Sales (TTM) | 2.32 |
| EV/Revenue | 0.739 |
| EV/EBITDA | 2.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $57.30M |
| Float | $46.25M |
| % Insiders | 0.62% |
| % Institutions | 78.45% |
Historical Volatility
HV 10-Day
70.46%
HV 20-Day
75.45%
HV 30-Day
73.73%
HV 60-Day
73.99%
HV Rank
43.3%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.86 target)
2
Strong Buy6
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/14/2026